Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type 2 Diabetes Mellitus (T2DM), Sarcope...
Phase NA
Enrollment 128
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to investigate the effects of a 12-week multimodal exercise intervention on middle-aged and older adults (aged 45\~85 years) with Type 2 Diabetes Mellitus (T2DM). The program combines supervised training, home-based sessions, and digital support to improve muscle function, physical performance, metabolic control, and quality of life.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Multimodal Exercise Program — Participants will engage in a 12-week multimodal exercise program comprising supervised training sessions, home-based exercises, and digital support. To facilitate adherence and proper technique, participants will also receive a "Diabetes and Muscle Health Handbook" as a training guide.

Primary Outcomes

  • Physical Function (5TSTS) (Change from Baseline at Week 12 and Week 24)
  • Handgrip Strength (HGS) (Change from Baseline at Week 12 and Week 24)
  • Skeletal Muscle Mass Index (SMI) (Change from Baseline at Week 12 and Week 24)
  • Sarcopenia Risk: Assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire combined with calf circumference measurement (SARC-CalF). (Change from Baseline at Week 12 and Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-23
Completion: 2026-08-15
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 128 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: yueh chu wu
Contact Information
Study Contact:
yueh chu wu WU YUEH CHU
886-952680613
yueh.chu46240@gmail.com
WU YUEH CHU
886-4-24739595
yueh.chu46240@gmail.com
Chung Shan Medical University Hospital
Interventions
  • Behavioral: Multimodal Exercise Program — Participants will engage in a 12-week multimodal exercise program comprising supervised training sessions, home-based exercises, and digital support. To facilitate adherence and proper technique, participants will also receive a "Diabetes and Muscle Health Handbook" as a training guide.
Study Locations (1 sites)
Chung Shan Medical University Hospital, Taichung, Taiwan 402306 Taiwan
Eligibility Criteria
Inclusion Criteria: * Diagnosed with both Type 2 Diabetes Mellitus (T2DM) and sarcopenia. * Maintained on a stable regimen of oral hypoglycemic agents. * Aged 45 years or older. * Capable of communicating effectively in Mandarin or Taiwanese. * Willing to provide informed consent or have it obtained from a legally authorized representative. Exclusion Criteria: * • Limited limb or joint function that prevents exercise (e.g., recent fractures or dislocations). * Communication barriers or severe emotional/psychological issues (e.g., uncontrolled depression or severe mental illness). * Severe cognitive impairment (e.g., dementia). * End-stage renal disease (ESRD). * Major comorbidities or complications, including active diabetic foot ulcers, amputation, recent myocardial infarction, severe autonomic neuropathy, or a history of stroke within the last 3 years.
Conditions Melanoma, Breast Cancer, Head & Neck Can...
Phase PHASE2, PHASE3
Enrollment 91
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective single-center interventional non-inferiority study where subjects are participating for one day for patients 18 years or older with melanoma, breast cancer or head \& neck cancer (including melanoma of head and neck area) and scheduled for a surgical SN procedure in the NKI-AvL without any contra-indication for Sonazoid contrast agent, such as an allergy to eggs or egg products. The primary objective is to assess the sensitivity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid). Secondary objectives are the specificity of CEUS for intra-operative SN localization, the time required to localize the SNs using CEUS and intraoperative usability of the CEUS-system. The primary endpoint is the sensitivity of the CEUS SN localization method. The conventional gamma probe will be used as ground truth comparison.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: Sonazoid — Intradermal injection of the ultrasound contrast agent Sonazoid.

Primary Outcomes

  • Sensitivity of the CEUS SN localization method (1 day)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2025-09-18
Completion: 2026-09-18
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 91 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Netherlands Cancer Institute
Collaborators: GE Healthcare
Principal Investigators:
  • Quirijn Tummers (PRINCIPAL_INVESTIGATOR) - The Netherlands Cancer Institute
Contact Information
Study Contact:
Marijn Hiep
+31205121751
ma.hiep@nki.nl
Marijn Hiep
+31205121751
ma.hiep@nki.nl
Netherlands Cancer Institute
Interventions
  • Drug: Sonazoid — Intradermal injection of the ultrasound contrast agent Sonazoid.
Study Locations (1 sites)
Netherlands Cancer Institute, Amsterdam, North Holland 1066 CX Netherlands
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or older * Patient has been diagnosed with cancer in the skin (melanoma), breast or head \& neck (including melanoma of head and neck area) * In case of a melanoma: it should be located in the limbs or head and neck area * Scheduled for a surgical SN procedure at the NKI-AvL * Patient provides written informed consent Exclusion Criteria: * Pregnancy * Any known clinically significant acute hypersensitivity reaction to the study medication, such as eggs or egg products * Other contra-indications for Sonazoid contrast agent, including arteriovenous cardiac or pulmonary shunt, serious coronary arterial disease and serious pulmonary disease
Conditions Asthma Exacerbations, Severe Asthma, Bro...
Phase NA
Enrollment 90
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Rationale: For patients with severe asthma that remain uncontrolled with exacerbations despite biologics or patients who are not eligible for biologics, there is no reimbursed treatment other than pulmonary rehabilitation in the Netherlands. Pulmonary rehabilitation is known to have a limited effect for a limited amount of time. Bronchial thermoplasty or bronchial ablation (BT) is a non-pharmacological treatment for asthma aiming to restore abnormal airway function by using an endobronchial approach. Previous RCT's reported efficacy on exacerbations and asthma related quality of life (AQLQ), but were performed before large availability of biologic treatments. Although a single BT treatment is not without costs, these costs seem to outweigh the costs that can be saved by the long-term (\>5 years) lowering effect of BT on the frequency of exacerbations and hospitalizations and omitting long term use of trials and switches of biologics. Therefore, the investigators hypothesize that BT, in the era of biologics, is superior (in terms of exacerbations and quality of life) over standard care and cost-effective in patients whose asthma remains uncontrolled despite optimal anti-inflammatory treatments including biologics, and the investigators propose to test this hypothesis in a RCT. Objective: To investigate the impact of BT as compared to standard of care in severe asthma patients that remain uncontrolled despite standard treatment including adequate doses of inhaled preventer therapies with or without biologics on: 1. rate of exacerbations 2. asthma related quality of life (AQLQ) 3. 1-year and 5-year cost-effectiveness and cost utility Study design: Investigator-initiated randomized, multicenter, parallel-group interventional RCT of severe asthma patients undergoing either BT (active arm) or standard care (control arm). Study population: Adult, uncontrolled severe asthma patients despite optimal medical therapy including one or more trials of treatment with a biologic or ineligible for biologic treatment AND 2 or more severe asthma exacerbations in the previous year AND FEV1 ≥ 50% predicted. Intervention: BT (active arm) versus standard care (control arm). Main study parameters/endpoints: The primary endpoint of this study is the between group difference in severe exacerbation rate after 12 months of follow-up. The main secondary endpoints are between group differences after 12 months of follow-up and within group differences before and after intervention or standard care. Parameters that will be explored are: AQLQ (minimal clinically important difference \>0.5), ACQ (minimal clinically important difference \>0.5), exacerbation rate (before and after BT) and hospitalizations (rate and % subjects).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Bronchial thermoplasty — Bronchial thermoplasty will be performed according to prior SOP's, in three sessions. First session RLL, second session LLL, third session RUL/LUL

Primary Outcomes

  • Exacerbation (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-09
Completion: 2029-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: ZonMw: The Netherlands Organisation for Health Research and Development
Contact Information
Study Contact:
P Bonta, Md PhD
+31 (0)20-7329509
p.i.bonta@amsterdamumc.nl
P Bonta
+31 (0)20-7329509
p.i.bonta@amsterdamumc.nl
amsterdam UMC
M van den Berge, Prof
m.van.den.berge@umcg.nl
UMCG
Interventions
  • Procedure: Bronchial thermoplasty — Bronchial thermoplasty will be performed according to prior SOP's, in three sessions. First session RLL, second session LLL, third session RUL/LUL
Study Locations (2 sites)
amsterdam UMC, Amsterdam, Netherlands
UMCG, Groningen, Netherlands
Eligibility Criteria
Inclusion Criteria: * adult (\>18 years) * severe uncontrolled asthma (defined as ACQ above 1.5) despite optimal medical therapy (GINA treatment step 5; alternative diseases excluded, therapy compliance and adequate inhalation technique confirmed) * 1 or more trials of treatment with a biologic or ineligible for biologic treatment * 2 or more severe asthma exacerbations in the previous year (defined as the need for a course of OCS or doubling dose of maintenance OCS for at least 3 consecutive days) * FEV1 ≥ 50% predicted after 400μg inhaled salbutamol or equivalent Exclusion Criteria: * chronic OCS therapy at a dose \>20 mg/day prednisone equivalent * 1 or more ICU admission for mechanical or endotracheal intubation for * asthma in the previous year. * anti-coagulation therapy that cannot be stopped temporarily * pregnancy * body mass index ≥35 * current or ex-smokers with \>20 pack years * DLCOc \<70% * Subject has a known sensitivity to medications required to perform bronchoscopy * Subject is using immunosuppressant therapy other than oral steroid therapy that impact on BT * Subject has bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/mm2 or known coagulopathy * Comorbidities that are a contra-indication for BT such as severe heart failure and other respiratory diseases including bronchiectasis, interstitial lung disease, emphy-sema, cystic fibrosis, mechanical upper airway obstruction, Churg-Strauss syndrome, and allergic bronchopulmonary aspergillosis (ABPA) * Subject uses an internal or external pacemaker or cardiac defibrillator..

IMST for Dementia Risk Reduction

NCT07349706
Recruiting
Conditions Systolic Blood Pressure, Blood Pressure,...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Using a 2-arm, RCT approach, the primary goal of the study is to evaluate the feasibility and preliminary efficacy of Inspiratory Muscle Strength Training (IMST) as a non-pharmacologic intervention to reduce cardiovascular and cognitive risks in older adults. Next, investigators will examine secondary effects of IMST on mood, sleep quality, systemic inflammation, and physical/motor function. Finally, investigators will assess participant adherence and acceptability ratings of using an 8-week home-based IMST protocol in a diverse older adult sample.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Device: Inspiratory Muscle Strength Training High-Resistance — Investigators will use POWERbreathe® Electronic IMST devices and manually set them to 75% of an individual's IPpeak, depending on their randomization, to the high-resistance IMST group or very low-resistance IMST (sham) group. All participants will complete 30 training breaths per day at home for 8 weeks.
  • Device: Inspiratory Muscle Strength Training Low-Resistance — Investigators will use POWERbreathe® Electronic IMST devices and manually set them to 15% of an individual's IPpeak, depending on their randomization, to the high-resistance IMST group or very low-resistance IMST (sham) group. All participants will complete 30 training breaths per day at home for 8 weeks.

Primary Outcomes

  • Change in systolic BP (Baseline, 8-weeks)
  • Change in executive cognitive functioning (Baseline, 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-17
Completion: 2026-12
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Florida State University
Collaborators: National Institutes of Health (NIH)
Contact Information
Study Contact:
Dr. Julia Sheffler
850-644-4199
julia.sheffler@med.fsu.edu
Florida State University
Interventions
  • Device: Inspiratory Muscle Strength Training High-Resistance — Investigators will use POWERbreathe® Electronic IMST devices and manually set them to 75% of an individual's IPpeak, depending on their randomization, to the high-resistance IMST group or very low-resistance IMST (sham) group. All participants will complete 30 training breaths per day at home for 8 weeks.
  • Device: Inspiratory Muscle Strength Training Low-Resistance — Investigators will use POWERbreathe® Electronic IMST devices and manually set them to 15% of an individual's IPpeak, depending on their randomization, to the high-resistance IMST group or very low-resistance IMST (sham) group. All participants will complete 30 training breaths per day at home for 8 weeks.
Study Locations (1 sites)
Florida State University, Tallahassee, Florida 32301 United States
Eligibility Criteria
Inclusion Criteria: * Ages 60-80 * Converted telephone MoCA total score≥18 * Presence of at least one dementia risk factor (e.g., MCI or subjective cognitive decline, hypertension \[SBP \>130 mmHg or on medication\], sedentary lifestyle \[\<150 min/week\], family history of dementia or self-reported APOE ε4 carrier, or mild sleep-disordered breathing; CAIDE total score \[\>5\] * Capable of independently completing or requiring minimal assistance with inspiratory muscle strength training (IMST) * Willing to adhere to the IMST protocol (approximately 5-10 minutes per day for 8 weeks) * Optional inclusion of inspiratory muscle weakness (MIP \<80 cmH₂O for men, \<70 cmH₂O for women) will also be assessed. Exclusion Criteria: * tMoCA \<18, or diagnosis of neurodegenerative illness at the discretion of principal investigator (except MCI) * Current evidence of any major psychiatric disorder including psychosis (at the discretion of principal investigator), bipolar disorder, severe major depression (PHQ-9 \> 20) * Unstable cardiovascular or pulmonary disease * Recent respiratory therapy or major medication changes * Self-reported severe untreated or unstable obstructive sleep apnea (OSA) * Recent start (within the past month) of CPAP or BiPAP, or recent use of inspiratory muscle training * Lung and eardrum injuries * Non-English speaking * Participants with a pacemaker or other medical implants containing magnets or electronics will be noted and excluded from body composition analyses.
Conditions Obesity or Overweight
Phase PHASE3
Enrollment 2000
Locations 203 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Combination Product: Placebo — Placebo will be volume-matched and administered once weekly using an integrated drug-device combination product.
  • Combination Product: Enicepatide — Enicepatide will be administered once weekly at the randomized dosing regimen using an integrated drug-device combination product.

Primary Outcomes

  • Percent (%) Change from Baseline in Body Weight at Week 72 (Baseline through Week 72)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-03-16
Completion: 2028-08-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hoffmann-La Roche
Principal Investigators:
  • Clinical Trials (STUDY_DIRECTOR) - Hoffmann-La Roche
Contact Information
Study Contact:
Reference Study ID Number: WC45725 https://forpatients.roche.com/ No attachments to email below.
888-662-6728 (U.S. Only)
global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Interventions
  • Combination Product: Placebo — Placebo will be volume-matched and administered once weekly using an integrated drug-device combination product.
  • Combination Product: Enicepatide — Enicepatide will be administered once weekly at the randomized dosing regimen using an integrated drug-device combination product.
Study Locations (203 sites)
Pinnacle Research Group, Anniston, Alabama 36207 United States
Alabama Clinical Therapeutics, Birmingham, Alabama 35235 United States
University of Alabama at Birmingham, Birmingham, Alabama 35294-3360 United States
Arizona Clinical Trials, Tucson, Arizona 85711 United States
University of California Irvine, Irvine, California 92612 United States
Artemis Institute for Clinical Research, LLC, San Diego, California 92123 United States
Diablo Clinical Research, Inc., Walnut Creek, California 94598 United States
Yale University, New Haven, Connecticut 06519 United States
Rophe Adult and Pediatric Medicine/SKYCRNG, Union City, Georgia 30291 United States
East-West Medical Research Institute, Honolulu, Hawaii 96814 United States
Eligibility Criteria
Inclusion Criteria: * Participants must have at screening: 1. Body mass index (BMI) greater than or equal to (≥)30.0 kg/m\^2; or 2. BMI ≥27.0 kg/m\^2 and \<30.0 kg/m\^2 with at least one weight-related comorbidity, such as prediabetes, hypertension, dyslipidemia, diagnosis of obstructive sleep apnea, or weight-related cardiovascular disease * History of ≥1 self-reported unsuccessful diet/exercise effort to lose body weight * Ability and willingness to self-administer the study drug (or receive an injection from a trained individual if visually impaired or with physical limitations) Exclusion Criteria: * History of Type 1 diabetes mellitus (T1DM) or T2DM, or history of ketoacidosis or hyperosmolar state/coma. Prior, but not current, diagnosis of gestational diabetes is allowed if no history of diabetes is recorded since. * Self-reported change in body weight \>5 kg within 3 months prior to screening * Obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptor deficiency or Prader-Willi syndrome) * Prior or planned surgical treatment for obesity. Liposuction or abdominoplasty if performed more than 1 year prior to screening is allowed. * Known clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) * History of acute or chronic pancreatitis or clinically significant gallbladder disease. History of acute pancreatitis caused by gallstones or clinically significant gallbladder disease is allowed if the participant had a cholecystectomy to resolve the problem at least 3 months prior to screening. * Poorly controlled hypertension at screening * Any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)/transient ischemic attack; Unstable angina; Hospitalization due to congestive heart failure. * Have a history of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder, or other serious mood or anxiety disorder). Participants with MDD or generalized anxiety disorder whose disease state is considered stable within 1 year prior to screening and expected to remain stable throughout the course of the study, in the opinion of the investigator, are allowed provided that they are not receiving prohibited medication. * Treatment with any approved or investigational GLP-1-RA-based therapy (e.g., GLP-1 receptor mono agonist, GLP-1/GIP receptor dual agonist, GLP-1/GIP/Gluc receptor triple agonist) within 6 months prior to randomization
Conditions Anxiety Depression
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized, double-blind, placebo-controlled study will enroll 60 individuals with mild-to-moderate anxiety depression. Following a 3-month intervention and a 1-month follow-up period, the study aims to: 1) evaluate the efficacy of probiotics by comparing anxiety, depression, and sleep scores to baseline; and 2) investigate the safety and underlying mechanisms by analyzing changes in serum biomarkers, gut microbiota, and related metabolites.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Probiotic — Participants receive Probiotic product once daily by oral, 60B CFU/day for 3 months.
  • Drug: Placebo — Participants receive Placebo once daily by oral for 3 months.
  • Combination Product: Escitalopram — Participants receive Escitalopram Oxalate Tablets once daily by oral, 10mg/day for 3 months.

Primary Outcomes

  • Hamilton Depression Rating Scale (HAM-D-24) (Baseline, Day 30, Day 90, Day 120 (follow up))
  • Hamilton Anxiety Rating Scale (HAM-A) (Baseline, Day 30, Day 90, Day 120 (follow up))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-15
Completion: 2027-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Moon (Guangzhou) Biotechnology Co., Ltd.
Contact Information
Study Contact:
Baojia Huang
86-020-31603387
huangbj@moonbio.com
IRB, First Affiliated Hosp, Guangdong Pharm Univ
86-020-87609616
gylunli@163.com
The First Affiliated Hospital of Guangdong Pharmaceutical University
Interventions
  • Drug: Probiotic — Participants receive Probiotic product once daily by oral, 60B CFU/day for 3 months.
  • Drug: Placebo — Participants receive Placebo once daily by oral for 3 months.
  • Combination Product: Escitalopram — Participants receive Escitalopram Oxalate Tablets once daily by oral, 10mg/day for 3 months.
Study Locations (1 sites)
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong China
Eligibility Criteria
Inclusion Criteria: * 1\) Age: 18-60 years old; Gender: male or female. * 2\) Meets the diagnostic criteria of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for a mild-to-moderate depressive or anxiety symptoms. * 3\) Hamilton Depression Rating Scale (HAM-D-24) score ≥ 8 or Hamilton Anxiety Rating Scale (HAM-A-14) score ≥ 7 at screening. * 4\) Has no used of anxiolytic or antidepressant medications (including traditional Chinese patent medicines), with the exception of Escitalopram Oxalate, within 2 weeks prior to the first dose. * 5\) For participants of childbearing potential (male or female): Must agree to use least one medically approve form of contraception (e.g., intrautering device \[IUD\], oral contraceptives, or condoms) throughout the trial. For female participants of childbearing potential: Must have a negative urine pregnancy test at screening and must be non-lactating. * 6\) The participant is willing and be able to provide written informed consent to participate in the study. Exclusion Criteria: * 1\) HAM-D-24 score ≥ 35 or HAM-A-14 score ≥ 29. * 2\) Presence of significant suicidal ideation. * 3\) History or current diagnosis of neuropsychiatric disorders such as schizophrenia or epilepsy. * 4\) History of head trauma (with loss of consciousness for \>10 minutes), other unstable major somatic diseases, or any somatic condition that could cause psychiatric symptoms. * 5\) Suspected intellectual disability. * 6\) History of alcohol or substance abuse prior to enrollment. * 7\) Cranial magnetic resonance imaging (MRI) reveals organic lesions. * 8\) Participants who are deemed unsuitable for the study by the investigator for any other reason.
Conditions Breast Cancer Early Stage Breast Cancer ...
Phase PHASE2, PHASE3
Enrollment 53
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, non-randomized clinical study aimed at investigating the potential benefits of continuous positive airway pressure (CPAP) support during radiotherapy for breast cancer. CPAP is a device commonly used to support breathing, for example in patients with sleep apnea. The investigators expect a reduction in radiation doses to the heart and/or lungs with CPAP-supported radiotherapy compared to standard radiotherapy (without CPAP), which may also lead to a decrease in radiation-induced heart and/or lung conditions in the long term. The study will also examine how the use of a CPAP device can be implemented in daily radiotherapy practice.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Non Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Continuous Positive Airway Pressure (CPAP) — Positive airway pressure (15cmH2O) delivered by a CPAP-device

Primary Outcomes

  • Mean heart dose (From enrollment to the end of treatment at +/-8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2025-02-11
Completion: 2027-06
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 53 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitaire Ziekenhuizen KU Leuven
Collaborators: VitalAire
Contact Information
Study Contact:
Aline Van der Vorst, MD
+3216340115
aline.vandervorst@uzleuven.be
Aline Van der Vorst, MD
+3216340115
aline.vandervorst@uzleuven.be
UZ Leuven
caroline.weltens@uzleuven.be
UZ Leuven
Interventions
  • Device: Continuous Positive Airway Pressure (CPAP) — Positive airway pressure (15cmH2O) delivered by a CPAP-device
Study Locations (1 sites)
UZ Leuven, Leuven, 3000 Belgium
Eligibility Criteria
Inclusion Criteria: 1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures 2. At least 40 years of age and 80 years or younger at the time of signing the Informed Consent Form (ICF) 3. Female patients 4. Patients that underwent breast conserving surgery (BCS) 5. Left-sided invasive BC / in situ carcinoma with indication for adjuvant RT (\<70 years old) 6. Left-sided invasive BC with indication for adjuvant locoregional RT (including RT of the regional lymph nodes) (70-80 years old) 7. Right-sided invasive BC with indication for adjuvant locoregional RT (including RT of the regional lymph nodes) 8. Prior chemotherapy allowed 9. Prior immunotherapy allowed 10. Prior / concomitant hormonal therapy allowed 11. Prior / concomitant HER2-targeted therapy allowed Exclusion Criteria: 1. Patient has active bullous lung disease, bypassed upper airway, pneumothorax, cerebral spinal fluid leaks, abnormalities of the cribriform plate (contra-indications for the use of CPAP) 2. Patient has history of major head trauma and/or pneumocephalus (contra-indications for the use of CPAP) 3. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CIP. 4. Female who is pregnant, breast-feeding or intends to become pregnant (which is a contra-indication for RT in general) 5. Male BC patients 6. Patients that underwent mastectomy Patients whose initial tumor was located just beneath the skin (defined as being less than 28mm below the breast surface), indicating the need for an electron boost 7. Patients requiring RT boost on positive lymph nodes 8. Distant metastasis 9. Breast implants in situ 10. Right-sided in situ carcinoma 11. Right-sided invasive BC only requiring local adjuvant RT (without irradiation of the regional lymph nodes, because the presumed benefit on cardiac doses of local right-sided breast irradiation is assumed to be rather small because of the left anatomical position of the heart) 12. Bilateral BC 13. Concomitant use of chemotherapy during RT 14. Substantial comorbidities, incompatible with RT or CPAP use, estimated by the treating radiation oncologist 15. Insufficient arm mobility to perform comfortable arm positioning in radiation treatment position, evaluated by the treating radiation oncologist 16. Other active oncological disease / treatment with the exception of non-melanoma skin cancer 17. Previous RT with overlapping RT fields with actual target volume
Conditions Primary Open Angle Glaucoma or Ocular Hy...
Phase NA
Enrollment 138
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to compare the short-term efficacy and safety of selective laser trabeculoplasty (SLT) to 0.005% latanoprost eye drops in lowering intraocular pressure (IOP) as primary therapy in treatment-naïve patients diagnosed as early to moderate primary open-angle glaucoma(POAG) or ocular hypertension (OHT) in the Lagos State University Teaching Hospital, Ikeja. The main questions it aims to answer are: 1. Will Selective Laser Trabeculoplasty be an equally effective treatment option compared with 0.005% Latanoprost eyedrops in reducing Intraocular Pressure when used alone as first-line therapy in Nigerian patients with POAG and OHT? 2. Will Selective Laser Trabeculoplasty record a similar safety profile compared with 0.005% Latanoprost when used independently as a primary therapy? 3. How will the quality of life of patients who undergo Selective Laser Trabeculoplasty treatment compare with patients on 0.005% Latanoprost eyedrops? Participants will be randomized to one of the two intervention groups. Group A(latanoprost group) will use 0.005% latanoprost eye drops every night at 2100hours(9.00pm) west African Time for 3 months. intraocular pressures will be monitored at intervals for a period of 3 months. Group B(SLT group) will have Laser treatment administered as a one-off treatment. intraocular pressures will be monitored at intervals for a period of 3 months. A record of side effects will be documented at each follow up visit

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: Selective laser trabeculoplasty — Selective laser trabeculoplasty is a laser based treatment that reduces intraocular pressure. it is a safe alternative to medical therapy and surgery.
  • Other: Latanoprost (0.005%) — Latanoprost is a prostaglandin analogue, a first-line ocular hypotensive medication because of it's high intraocular pressure lowering efficacy.

Primary Outcomes

  • Percentage intraocular pressure reduction from baseline (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-15
Completion: 2026-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 138 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lagos State Health Service Commission
Principal Investigators:
  • Prof B. Adekoya, FWACS, MD (STUDY_DIRECTOR) - Lagos State University
Contact Information
Study Contact:
Anne I. Abang-Obi, MBBS
+234 7061339223
iyeundiandeye@gmail.com
Chidinma C. Onyejekwe, FMCOph
+234 7060645714
LASUTH Department of Ophthalmology
018980537
lasuthophthalmology@gmail.com
Lagos State University teaching Hospital Eye Institute
Interventions
  • Procedure: Selective laser trabeculoplasty — Selective laser trabeculoplasty is a laser based treatment that reduces intraocular pressure. it is a safe alternative to medical therapy and surgery.
  • Other: Latanoprost (0.005%) — Latanoprost is a prostaglandin analogue, a first-line ocular hypotensive medication because of it's high intraocular pressure lowering efficacy.
Study Locations (1 sites)
Lagos State University teaching Hospital Eye Institute, Ikeja, Lagos Nigeria
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 18years and above. 2. Patients newly diagnosed as Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). 3. Patients with elevated IOP greater than 21mmHg (average of 3 measurements taken on 3 different clinic visits). 4. Patients categorized as early or moderate glaucoma POAG (cup -disc ratio 0.5 to 0.7, visual field analysis MD - 6dB to -12dB and disc damage likelihood score (DDLS) 5 to 7) on funduscopy, Optical coherence tomography, and fundus photograph 5. Patients who agree to participate in the study after informed consent. Exclusion Criteria: 1. A prior medical, surgical, or laser treatment for glaucoma 2. Patients diagnosed with primary congenital glaucoma or secondary glaucoma 3. Advanced glaucoma (CDR greater than 0.8, visual field analysis MD more than -12dB and DDLS stage 8 and above) 4. Patients with cloudy cornea or corneal opacity that would impair the view of the anterior chamber angles, fundus, or give false IOP readings 5. Patients with media opacity, such as cataracts, vitreous haze, or vitreous hemorrhage that prevents examination of the posterior segment. 6. Patients who have undergone previous ocular surgeries (cataract surgery, trabeculectomy). 7. Patients with a history of ocular trauma or uveitis 8. Pregnant and lactating women. \-
Conditions Breast Cancer
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

"Moving Together" (Juntas en Movimiento) is a hospital-based, comprehensive, and personalized exercise service designed for women diagnosed with breast cancer. This implementation study aims to evaluate the feasibility, safety, and impact of integrating a free, tailored exercise program into routine clinical care at Hospital Clínico San Carlos in Madrid, Spain. The program offers multiple participation options-supervised in-person, supervised online, autonomous at home, or autonomous at a fitness center-allowing patients to choose based on their preferences, limitations, and treatment phase (pre-surgery, during chemotherapy/radiotherapy, or survivorship). All exercise options are adapted to individual needs and include aerobic and resistance training components. The study uses a real-world implementation science approach, guided by the Consolidated Framework for Implementation Research (CFIR), to assess clinical, physical, and psychological outcomes such as quality of life, cardiorespiratory fitness, muscle strength, body composition, and adherence to physical activity. Data are collected through clinical records, physical assessments, validated questionnaires, and wearable technology. This pioneering initiative in Spain seeks to establish exercise as a standard complementary therapy in oncology care, bridging the gap between scientific evidence and clinical practice, and promoting long-term health and well-being in breast cancer patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Supervised in-person exercise training — Participants attend 60-minute, twice-weekly exercise sessions at GO fit Vallehermoso. Sessions include warm-up, aerobic and resistance training, and cool-down. Exercises are tailored to the patient's treatment phase (pre-surgery, during chemotherapy/radiotherapy, or survivorship) and adjusted based on symptoms like fatigue or pain. Heart rate is monitored in real time. Groups are formed by treatment phase and physical capacity to ensure safety and personalization.
  • Other: Supervised Online Exercise Training — Participants follow the same structure as the in-person group but attend sessions via live video conferencing. They receive equipment and training on using the MYZONE app for heart rate monitoring. Sessions are interactive, allowing real-time feedback and social support. This option is designed for patients with mobility, time, or travel limitations.
  • Other: Home-Based Autonomous Exercise Program — Participants receive structured exercise guidelines to follow independently at home. Programs include aerobic and strength exercises using bodyweight or household items, with three levels of progression. Training is recommended 1-3 times per week. Participants track activity using a diary and smartphone accelerometer. Programs are adapted to treatment phase and personal capacity.
  • Other: Gym-Based Autonomous Exercise Program — Participants follow individualized exercise guidelines at the gym, using gym equipment for strength and aerobic training. The program is self-directed but based on the same structure and progression as supervised programs. Activity is tracked via accelerometers and exercise logs. Participants choose this option based on preference and access to gym facilities.
  • Other: Usual Care Without Structured Exercise — Participants in this group do not receive any structured exercise intervention. They continue with standard medical care and follow-up as prescribed by their oncology team. They undergo the same clinical, physical, and psychological assessments as the intervention groups to allow for comparison of outcomes.

Primary Outcomes

  • Change in Health-Related Quality of Life (HRQoL) measured by the EORTC QLQ-C30 (Baseline, 4 months, 8 months, and 12 months after enrollment)
  • Change in Health-Related Quality of Life (HRQoL) measured by the EORTC QLQ-BR42 (Baseline, 4 months, 8 months, and 12 months after enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-06
Completion: 2030-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GO fit Lab- Ingesport
Contact Information
Study Contact:
Alfonso Jiménez
+34 915902959
alfonso.jimenez@urjc.es
GOfit Vallerhermoso
Ana Myriam Lavín Pérez
ana.lavin.perez@urjc.es
GOfit Vallerhermoso
María Josefa Herrera de la Muela
GOfit Vallerhermoso
Interventions
  • Other: Supervised in-person exercise training — Participants attend 60-minute, twice-weekly exercise sessions at GO fit Vallehermoso. Sessions include warm-up, aerobic and resistance training, and cool-down. Exercises are tailored to the patient's treatment phase (pre-surgery, during chemotherapy/radiotherapy, or survivorship) and adjusted based on symptoms like fatigue or pain. Heart rate is monitored in real time. Groups are formed by treatment phase and physical capacity to ensure safety and personalization.
  • Other: Supervised Online Exercise Training — Participants follow the same structure as the in-person group but attend sessions via live video conferencing. They receive equipment and training on using the MYZONE app for heart rate monitoring. Sessions are interactive, allowing real-time feedback and social support. This option is designed for patients with mobility, time, or travel limitations.
  • Other: Home-Based Autonomous Exercise Program — Participants receive structured exercise guidelines to follow independently at home. Programs include aerobic and strength exercises using bodyweight or household items, with three levels of progression. Training is recommended 1-3 times per week. Participants track activity using a diary and smartphone accelerometer. Programs are adapted to treatment phase and personal capacity.
  • Other: Gym-Based Autonomous Exercise Program — Participants follow individualized exercise guidelines at the gym, using gym equipment for strength and aerobic training. The program is self-directed but based on the same structure and progression as supervised programs. Activity is tracked via accelerometers and exercise logs. Participants choose this option based on preference and access to gym facilities.
  • Other: Usual Care Without Structured Exercise — Participants in this group do not receive any structured exercise intervention. They continue with standard medical care and follow-up as prescribed by their oncology team. They undergo the same clinical, physical, and psychological assessments as the intervention groups to allow for comparison of outcomes.
Study Locations (1 sites)
GOfit Vallerhermoso, Madrid, Madrid 28003 Spain
Eligibility Criteria
Inclusion Criteria: * Women aged 18 years or older. * Diagnosed with any type and stage of breast cancer. * Receiving care at Hospital Clínico San Carlos (Madrid, Spain). * Willing and able to provide informed consent. * Eligible to participate in physical activity based on clinical evaluation. Exclusion Criteria: * Medical contraindications to physical exercise. * Severe uncontrolled conditions (whether related to cancer treatment or not). * Diagnosis of recurrent breast cancer. * Refusal or inability to sign the informed consent form.
Conditions Alzheimer s Disease, Major Depressive Di...
Phase Not Applicable
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective, single-center, repeated-measures study evaluates whether VR-based eye-tracking pupillometry can provide a practical, non-invasive biomarker of cognitive impairment and its progression over time. Pupil responses are linked to brain arousal systems relevant to cognitive dysfunction, including the locus coeruleus, which is affected early in Alzheimer's disease. Adults aged 18-80 years will be assigned to one of four cohorts (n=35 per cohort): i) Alzheimer's disease (supported by CSF biomarkers), ii) mild cognitive impairment (MCI) without Alzheimer's Disease, iii) depressive disorder with cognitive impairment, iv) healthy controls. Participants will undergo initial assessments at baseline and follow-up visits after 3 and 6 months. At each visit, pupil responses and behavioral metrics are recorded during a pupillary light reflex paradigm, a resting-state fixation block, a working-memory task (N-back), and a reward task. Pupillometric and behavioral metrics will be compared across cohorts and related to routine neuropsychological measures (MoCA, CERAD) and available clinical biomarkers (CSF markers; blood biomarkers). The primary objective is to determine whether task-evoked pupil response profiles sensitively quantify cognitive impairment, differ between cohorts, and track change over time. The long-term goal is to validate an easy-to-use, outpatient-compatible assessment to support objective characterization and monitoring of cognitive disorders.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Task-evoked pupil dilation during N-Back (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Max-Planck-Institute of Psychiatry
Principal Investigators:
  • Victor I. Spoormaker, PhD (PRINCIPAL_INVESTIGATOR) - Max-Planck-Institute of Psychiatry
Contact Information
Study Contact:
Eva Vidovic, MD
089-30622-1402
eva_vidovic@psych.mpg.de
Victor I. Spoormaker, PhD
089-30622-1402
ambulanz@psych.mpg.de
Eva Vidovic, MD
089 30622 1402
ambulanz@psych.mpg.de
Max Planck Institute of Psychiatry
Interventions
N/A
Study Locations (1 sites)
Max Planck Institute of Psychiatry, München, Bavaria 80804 Germany
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent. 2. Age 18-80 years. 3. Ability to read and understand German. 4. For patient cohorts: suspected or confirmed diagnosis of AD/MCI/depressive disorder with cognitive impairment according to clinical assessment and routine documentation. Exclusion Criteria: 1. Acute suicidality (e.g. BDI suicidality item \> 1). 2. Change of psychotropic medication within the last 4 weeks. 3. Lifetime psychotic disorder (ICD-10 F20-29). 4. Lack of capacity to consent. 5. Lifetime bipolar disorder (ICD-10 F31). 6. Acute substance abuse or harmful use of alcohol or other psychoactive substances. 7. Parkinson's syndrome (ICD-10 G20). 8. Multiple sclerosis (ICD-10 G35). 9. Stroke within the last 12 months.
Conditions Triple -Negative Breast Cancer, Breast C...
Phase PHASE2
Enrollment 416
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Triple-negative breast cancer (TNBC), defined by the lack of ER, PR and HER2 expression, is refractory to endocrine therapy and anti-HER2 agents. Chemotherapy was once the mainstay for advanced TNBC, but its limited efficacy necessitates optimized therapeutic strategies. TNBC's high TIL infiltration and elevated PD-L1 expression confer sensitivity to immune checkpoint inhibitors (ICIs), with ICI-chemotherapy combinations initially establishing first-line standard status. Emerging clinical evidence shows that ICI-antibody-drug conjugate (ADC) combinations outperform ICI-chemotherapy regimens, yet immune-related adverse events (irAEs) remain a critical clinical challenge. Expert consensus recommends continuing ICI therapy in advanced TNBC patients achieving CR, PR or SD after ICI-based combination therapy until disease progression or intolerable toxicity. Mechanistically, once ICIs reach target receptor saturation, dose escalation or high-frequency administration fails to boost efficacy but raises toxicity risk. Thus the investigators hypothesize that an ICI maintenance strategy with fixed dose and extended intervals can preserve efficacy, reduce toxicity, improve patient compliance, enhance quality of life and alleviate economic burden for advanced TNBC patients with CR/PR/SD after ICI-chemotherapy or ICI-ADC treatment.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Extended-Dose Interval Immunotherapy — During the maintenance therapy phase, the dose of PD-1 inhibitors is maintained at the same level as in the standard treatment phase, with the dosing interval extended to every 6 weeks (q6w).
  • Drug: Standard-Dose Interval Immunotherapy — During the maintenance therapy phase, the dosage and dosing interval of PD-1 inhibitors are consistent with those in the standard therapy phase, administered every 3 weeks (q3w).

Primary Outcomes

  • mPFS (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-12-31
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 416 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Jieqiong Liu
86-13922272706
liujieqiong01@163.com
Jieqiong Liu
086-13922272706
liujieqiong01@163.com
Breast Tumor Center, Sun Yat-sen Memorial Hospital
Interventions
  • Drug: Extended-Dose Interval Immunotherapy — During the maintenance therapy phase, the dose of PD-1 inhibitors is maintained at the same level as in the standard treatment phase, with the dosing interval extended to every 6 weeks (q6w).
  • Drug: Standard-Dose Interval Immunotherapy — During the maintenance therapy phase, the dosage and dosing interval of PD-1 inhibitors are consistent with those in the standard therapy phase, administered every 3 weeks (q3w).
Study Locations (1 sites)
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong 510000 China
Eligibility Criteria
Inclusion Criteria: 1. Voluntary consent to participate in this study and signing of the informed consent form. 2. The age of the signatory of the informed consent form should be ≥18 years old and ≤70 years old. 3. Advanced (locally recurrent inoperable or metastatic) TNBC confirmed by histology or cytology, defined as ER-negative, PR-negative, and HER2-negative. 4. PD-L1 IHC detection in tumor tissue with a CPS score ≥1. 5. Have received first-line standard immunotherapy combined with chemotherapy or immunotherapy combined with ADC and completed 6 cycles, with the last dose administered no more than 28 days before randomization. 6. The therapeutic efficacy was confirmed as CR, PR or SD after 6-cycle standard treatment according to the RECIST v1.1 criteria. 7. Plan to continue receiving immunotherapy. 8. An Eastern Cooperative Oncology Group performance-status score of 0 or 1. 9. The expected survival period exceeds 12 weeks. 10. Adequate organ function:. 11. No mental or intellectual abnormalities. 12. Willing and able to comply with the trial protocol during the trial period. 13. Female subjects of childbearing potential must agree to use highly effective contraceptive measures starting at least 7 days before the first dose and continuing until 24 weeks after the last dose. The serum pregnancy test result must be negative within 7 days prior to the first dose. Exclusion Criteria: 1. Untreated active brain metastases or meningeal metastases. 2. Concomitant other malignant tumors with progression within the recent 5 years or requiring active treatment (excluding adequately treated and controlled carcinoma in situ and non-melanoma skin cancer). 3. Concomitant severe non-malignant diseases that would affect the patient's compliance or put the patient at risk. 4. Concomitant active infection. 5. Receiving other anti-tumor therapies or participating in other interventional clinical trials. 6. Inflammatory breast cancer. 7. Dementia, intellectual disability, or any mental disorders that hinder the understanding of the informed consent form. 8. History of allergic reactions to any components of the study drugs or existing contraindications to their use. 9. Presence of any active autoimmune diseases or history of autoimmune diseases. 10. Presence of poorly controlled clinical cardiac symptoms or diseases, such as:1) Heart failure of NYHA class II or above;2) Unstable angina pectoris;3) Myocardial infarction occurring within 1 year;4) Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention. 11. Presence of grade ≥3 toxicities related to prior treatments that restrict the continuation of maintenance therapy. 12. History of immunodeficiency, including HIV positivity, active HBV/HCV infection, other acquired or congenital immunodeficiency diseases, and history of organ or allogeneic stem cell transplantation. 13. Vaccination with live vaccines within 4 weeks prior to the administration of study drugs or planned vaccination during the study period. 14. Prior administration of irinotecan, topotecan, or any other topoisomerase I inhibitors (including investigational topoisomerase I inhibitors), or known history of allergies to the above-mentioned drugs. 15. Use of systemic glucocorticoids at a dose exceeding 10 mg/day of prednisone equivalent within 14 days prior to the administration of study drugs, or planned long-term use of the above dose during the study period (topical, inhaled, or short-term (≤7 days) pulse doses ≤10 mg/day of prednisone equivalent, or physiological dose replacement therapy are allowed for inclusion). 16. Need for use of any immunosuppressants within 14 days prior to the administration of study drugs or planned use during the study period. 17. Pregnant or lactating women, or women of childbearing potential who refuse to accept contraceptive measures. 18. Patients who are difficult or impossible to follow up. 19. Subjects judged by the investigator to have conditions that may affect compliance or other circumstances making them unsuitable for inclusion.
Conditions Breast Cancer
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This single-institution pilot study uses a pre- and post-implementation design to evaluate the implementation of ICG fluorescent imaging for sentinel lymph node biopsy (SLNB) in an Italian hospital.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Procedure: ICG used as a tracer for sentinel lymph node — ICG used as a tracer for sentinel lymph node instead of technetium 99
  • Procedure: technetium 99 used as a tracer for sentinel lymph node — technetium 99 used as a tracer for sentinel lymph node instead of ICG

Primary Outcomes

  • Identification rate of SLNs achieved by 99mTc-nanocolloid or the fluorescent signal of ICG (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-07
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Casa di Cura Dott. Pederzoli
Contact Information
Study Contact:
Francesca Guerini, MD
+39 0456444193
urc@ospedalepederzoli.it
Ospedale P. Pederzoli Casa di Cura Privata S.p.A.
Interventions
  • Procedure: ICG used as a tracer for sentinel lymph node — ICG used as a tracer for sentinel lymph node instead of technetium 99
  • Procedure: technetium 99 used as a tracer for sentinel lymph node — technetium 99 used as a tracer for sentinel lymph node instead of ICG
Study Locations (1 sites)
Ospedale P. Pederzoli Casa di Cura Privata S.p.A., Peschiera del Garda, Verona Italy
Eligibility Criteria
Inclusion Criteria: * Clinically node-negative, DCIS or invasive stage T1-T3 breast cancer confirmed by biopsy * Preoperative axillary ultrasound to confirm clinical node-negative status * Indication for breast cancer surgery with SLNB via axillar incision * Written informed consent according to national regulations Exclusion Criteria: * Patients \< 18 years old. * Indication for breast cancer surgery with SLNB via mastectomy incision * Known allergy for ICG, intravenous contrast or iodine * History of axillary lymph node dissection * Pregnancy or breast-feeding * Psychological, familial, sociological or geographical factors that could potentially hamper compliance with the study protocol